Rapport Therapeutics Bolsa (NASDAQ: RAPP)

Últimas noticias sobre Rapport Therapeutics (NASDAQ:RAPP) Bolsa

Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Sportsman'sSaratoga,Springs,,Utah,,Usa,-,Nov,30,,2024:,Sportsman's,Warehouse

AEHL

AGMH

BIAF

DGLY

GRFS

NCNO

NMAX

QUAD

RAPP

RSLS

SAMG

SBFM

SPWH

STSS

SYRA

Sportsman&#39;s Warehouse sorprende con ingresos y ganancias inesperadas: conoce las cifras que hicieron subir sus acciones.

Acciones de Sportsman&#39;s Warehouse (SPWH) se disparan un 39%; Aquí están 20 acciones moviéndose en premercado

GameStop Corp.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BHIL

BSGM

CISO

CLEU

GDHG

HUMA

IMTE

NYXH

ORKA

PTPI

SURG

THTX

TXMD

WINT

ZYBT

El premercado de hoy revela fuertes movimientos bursátiles tras informes financieros y aprobaciones clave en sectores críticos.

Las acciones de GameStop (GME) suben alrededor del 13%; Aquí están 20 acciones que se mueven en el premercado

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics Inc

<p>Ascent Solar Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTI#NASDAQ">ASTI</a>) ("Ascent" or the "Company"), the leading U.S. innovator in the design and manufacture of featherweight, flexible, and durable CIGS thin-film photovoltaic (PV) solutions, today announced the pricing of a public offering of an aggregate of 1,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 1,000,000 shares of common stock (the "Warrants"), at a combined public offering price of $2.00 per share (or per pre-funded warrants in lieu thereof) and accompanying Warrant. The Warrants will have an exercise price of $2.00 per share, will be exercisable immediately upon issuance, and will expire on the five-year anniversary of the initial issuance date. The closing of the offering is expected to occur on or about June 30, 2025, subject to the satisfaction of customary closing conditions.</p>
<p>H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.</p>
<p>The aggregate gross proceeds to the Company from the offering are expected to be $2.0 million before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital, product development activities, general and administrative expenses and other general corporate purposes.</p>


Offerings

ASTI

Ascent Solar Prices $2M Public Offering of 1M Shares and 1M Warrants At A Combined Price Of $2.00

<p>You may not have noticed, but on Sunday, June 22, the world of cars changed forever. </p>
<p>That was when regular consumers for the first time got to take a $4.20-ride around Austin, Texas, in driverless taxis, courtesy of <strong>Tesla</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and <strong>Elon Musk</strong>.</p>
<p>The <a href="https://www.benzinga.com/markets/tech/25/06/46045542/tesla-launches-robotaxi-in-austin-elon-musk-calls-it-a-culmination-of-a-decade-of-hard-work">robotaxi test</a> took place in a sectioned, geofenced area of Austin, with selected Tesla owners in the back seat, a Tesla employee on hand for emergencies in the front passenger seat, and no one physically behind the wheel.</p>
<p>By the end of the day, feedback began rolling in on social media, and it was overwhelmingly positive.</p>
<p>"We took two approximately 15-minute rides around Austin and the key takeaways are that it was a comfortable, safe, and personalized experience," <a href="https://www.benzinga.com/markets/tech/25/06/46049232/dan-ives-hails-very-impressive-robotaxi-ride-in-austin-predicts-55-upside-for-tesla-stock-as-golden-age-begins">noted</a> <strong>Dan Ives</strong>, a Wedbush analyst, in a research note released later in the day on June 22.  </p>
<p>"The robotaxis we experienced today were foundational, and there is a path for the future where these robotaxis may also have Grok integration, interior customization, and a much more user-centric focus as there&#8217;s no longer a need to focus on the driver experience," Ives added.</p>
<p>He&#8217;s not alone.</p>
<p>"Today transportation changed FOREVER!" said<a href="https://x.com/JoshWest247/status/1932618098777137590"> JoshWest247 on X</a>, after his test drive. "Robotaxi=FREEDOM!"</p>
<p>Amidst talk of the Tesla<strong> </strong>robotaxi adding $1 trillion in value to the company, plans are afoot to manage vehicle growth gradually, with 50 in operation by the fourth quarter of 2025 in Austin and 1,000-plus on the streets by year-end 2026. Tesla is also mapping out a California robotaxi expansion, targeting 2026, pending approval from the state. Over time, Tesla aims to replace Model Ys with its Cybercab robotaxi vehicle.</p>
<p>At first glance, the driverless future is golden, although there's plenty of highway miles ahead for industry leaders. At the very least, the Austin tests may serve as the launch point of a revolutionary new industry that changes everything we think we know about road transportation.</p>
<p>"Tesla's autonomous taxi test in Austin signals a very real shift toward mainstream adoption of robotaxis, not just a speculative future," said <strong>Kazimieras Urbonas</strong>, car analyst and supplier excellence manager at Ovoko, a technology-based auto parts company. "The major takeaway is that we're no longer just talking about autonomy, we're piloting it at scale. This shows growing maturity in Tesla's FSD (Full Self-Driving) tech, which will inevitably pressure other automakers to speed up their timelines."</p>
<p>According to Urbonas, driverless transport will be one of the most transformative changes in mobility, comparable to the transition from combustion to electric power. "While rollout will vary by region due to infrastructure and legal constraints, the long-term implications for logistics, ride-hailing, and even public transport are enormous," he noted. "Think safer roads, lower costs, and new urban design models."</p>
<p>As the smoke cleared from the test date, Wall Street commenced buzzing over the trading prospects of autonomous vehicle makers and which companies may be left behind as history is made with the first driverless taxi rollout.</p>
<h2 class="wp-block-heading"><strong><em>Independence From Trading Tool Chaos</em></strong></h2>
<p><em>Stop switching between news apps, scanners, and alert systems that don't communicate with each other. Get our exclusive Benzinga Wire, smart filtering, and integrated tools in one professional platform. <strong>Declare Trading Independence <a href="https://www.benzinga.com/pro/register/4th-of-july-sale/?utm_campaign=bzpro-4th&amp;el=Res[…]mail}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD062825">HERE</a> at 60% off.</strong></em></p>
<p>Which stocks will rock on as robotaxis get all too real, and which will go the way of horse and carriage after Henry Ford rolled up in a small, four-wheeled vehicle he called a Quadricycle on June 4, 1896? Here are a few candidates on both sides of the road.</p>
<h2 class="wp-block-heading">Winners</h2>
<h3 class="wp-block-heading">Tesla</h3>
<p><strong>Benzinga Quality Ranking: 83.17</strong></p>
<p>The carmaker's share price only popped by 1.2% in the five days following the Austin robotaxi tests, but the moment may have established Tesla as the king of the driverless transport hill, for now at least. Tesla has a lot on the line with autonomous vehicles, which comprises about 59% of the company's price target, amounting to $181 per share or $800 billion in implied value, according to RBC Capital.</p>
<p>"If Tesla can iron out safety concerns and scale fast, they could dominate the driverless car industry," said John Ellmore, EV Fleet Editor at UK-based KnowYourBusiness.</p>
<h3 class="wp-block-heading">Alphabet&nbsp;</h3>
<p><strong>Benzinga Quality Ranking: 86.66</strong></p>
<p><strong>Google's </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Waymo driverless taxi doesn't get the massive press that Tesla and Musk garner, but it's actually ahead of the curve on robotaxi testing. It's already up and running in four U.S. cities, with plans to roll out its autonomous vehicles in 17 more. It intends to launch commercially by 2026 or 2027. All told, Waymo is expected to account for 10% of the AV marketplace by the end of the decade.</p>
<h3 class="wp-block-heading">Nvidia</h3>
<p><strong>Benzinga Growth Ranking: 98.61</strong></p>
<p>Chipmaking giant <strong>Nvidia </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) should benefit from the headway made by companies like TSLA and Waymo. "Nvidia's chips already power most autonomous driving systems," Urbonas said. "More driverless vehicles equal more demand."</p>
<h2 class="wp-block-heading">Losers</h2>
<h3 class="wp-block-heading">Uber</h3>
<p><strong>Benzinga Growth Ranking: 97.49</strong></p>
<p><strong>Uber's </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) stock hasn't suffered from Tesla's wave of media coverage following its Austin testing weekend – it's up 8.36% this week alone. Analysts point to Uber's burgeoning relationship with Waymo and the fact that the company has entered into AV testing with Volkswagen and Pony AI.</p>
<p>Yet over the long haul, Uber doesn't seem to have a clear-cut path in competing with driverless taxis, which promise to be cheaper and more pervasive once Tesla and Waymo vehicles hit the open road.</p>
<h3 class="wp-block-heading">Lyft</h3>
<p><strong>Benzinga Growth Ranking: 56.43</strong></p>
<p>San Francisco-based ride-sharing company <strong>Lyft </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) has seen its shares rise to the mid-teens (it was trading at $15.46 on June 27). Its stock is up 19% year-to-date. The firm plans to roll out its own AV line in Dallas over the next few months, with plans to expand to Canada and Europe the following year.</p>
<p>Still, the math is working against Lyft. It's already behind Uber in the rideshare market by a 30%-to-70% ratio. The company will be hard-pressed to compete with industry heavyweights like Tesla, which is expected to reach a $1 trillion market share within the next five years.</p>
<p>"Traditional ride-hailing platforms like Uber and Lyft could see margin compression as autonomous fleets reduce human labor costs," Urbonas added.</p>
<h3 class="wp-block-heading">Traditional auto makers and auto parts companies</h3>
<p>Legacy automakers without robust EV and autonomous vehicle pipelines could fall behind. </p>
<p>"That's particularly the case with those companies reliant on fleet sales and dealer-driven models," Urbonas said. "Auto parts suppliers focused on mechanical components (e.g., internal combustion parts) could also struggle as electric-autonomous systems reduce part complexity and maintenance."</p>
<p>Traditional auto repair chains could also struggle, and they won't be alone.</p>
<p>"Fewer moving parts mean fewer breakdowns," said <strong>Luis Montes</strong>, a heavy-duty transport equipment expert and chief editor at Fortis HD.  "Fuel providers take a hit if the shift is electric-heavy. Public transport might also lose funding if private driverless fleets get political backing. Even parking real estate will lose relevance if cars start circulating instead of idling."</p>
<p><em>Editorial content from our expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.</em></p>
<p><em>Photo: Shutterstock</em></p>


Opinion

GOOG

LYFT

NVDA

TSLA

UBER

Winning And Losing Stocks From Tesla's Driverless Taxi Test

General

ABAT

American Battery Technology To Be Added To Russell 2000 And Russell 3000 Indexes, Effective June 30, 2025

<p>U.S. Senator Maggie Hassan (D-NH) is intensifying her scrutiny of <strong>GSK Plc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) over the company's decision to pull its widely used asthma inhaler, Flovent HFA, from the market.</p>
<p>One year after the discontinuation, Hassan launched a formal investigation into the move, raising alarms about patient access, skyrocketing costs, and the financial burden placed on Medicaid.</p>
<p>Flovent HFA had long been the most <a target="_blank" href="https://www.hassan.senate.gov/news/press-releases/senator-hassan-launches-investigation-into-gsk-on-impact-of-its-discontinuation-of-childrens-asthma-inhaler" rel="noreferrer noopener">prescribed</a> controller inhaler for young children with asthma. After it was removed from the market in January 2024, GSK partnered with Prasco Laboratories to distribute an authorized generic version.</p>
<p><strong><em>Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45406673/gsk-to-buy-phase-3-ready-liver-disease-drug-for-up-to-2-billion" rel="noreferrer noopener">GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion</a></em></strong></p>
<p>This rebranded product has been significantly more expensive for patients, allowing GSK to avoid an estimated $367.6 million in Medicaid rebates in 2024 alone. Instead, Medicaid spent over $550 million on the authorized generic in 2024.</p>
<p>In a <a target="_blank" href="https://www.hassan.senate.gov/imo/media/doc/2025-06-27%20Hassan%20to%20GSK%20-%20Copy_Redacted.pdf" rel="noreferrer noopener">letter</a> to the CEO, Emma Walmsley, Senator Hassan criticized the maneuver as a corporate strategy that prioritized profits over patients, stating that it threatened the lives of children and placed undue financial strain on families. "GSK's decision to allow a different company to sell the same product in a more expensive form has endangered children and fleeced taxpayers," she said.</p>
<p>Hassan <a target="_blank" href="https://www.hassan.senate.gov/news/press-releases/senator-hassan-presses-big-pharma-company-to-restore-access-to-low-cost-asthma-inhalers-for-children" rel="noreferrer noopener">urged</a> GSK to restore the original Flovent HFA and work with Prasco to reduce the cost of the generic version.</p>
<p>In her May 2024 letter, Hassan questioned why GSK discontinued Flovent HFA while keeping other brand-name inhalers on the market and capping their prices. GSK's response did not clarify this; instead, it shifted responsibility to Prasco for pricing decisions and formulary negotiations.</p>
<p>While GSK claimed the generic was priced 35% lower than branded Flovent, previous rebates on the original product had made it significantly more affordable. The absence of such rebates for the generic has led many insurers and pharmacy benefit managers to delay or deny coverage.</p>
<p>The consequences have been severe. Pediatric providers reported that Flovent HFA was the only inhaler compatible with spacer devices for infants and young children.</p>
<p>Its removal has limited treatment options, especially for patients with eosinophilic esophagitis or those who cannot tolerate alternatives. Meanwhile, other substitute inhalers, like Asmanex HFA and Alvesco, have faced shortages or limited insurance coverage throughout 2024.</p>
<p>A study published in October 2024 revealed a 17.5% increase in asthma-related hospitalizations in the three months after Flovent's removal, followed by a 24.1% increase over the next three to six months compared to previous years. ICU admissions showed similar spikes.</p>
<p>Beyond health outcomes, the financial impact has been substantial. A Johns Hopkins analysis found that Medicaid spent an estimated $551.8 million on the authorized generic in 2024 — nearly double what it might have spent under the original rebate structure. Even insured patients reported paying up to $150 per inhaler.</p>
<p>Senator Hassan's investigation aims to hold GSK accountable and prevent similar corporate tactics that bypass rebate obligations at the expense of public health.</p>
<p><strong>Price Action: </strong>GSK stock is trading lower by 0.03% to $38.54 at the last check Friday</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><em><a href="https://www.benzinga.com/analyst-stock-ratings/upgrades/25/06/46146899/this-is-googles-secret-weapon-to-outpace-chatgpt-in-the-search-war" target="_blank" rel="noreferrer noopener">This Is Google's Secret Weapon To Outpace ChatGPT In Search War</a></em></strong></li>
</ul>
<p><em>Photo via Shutterstock</em></p>


Government

Large Cap

Legal

GSK Rebranded Flovent Asthma Inahler For Children To Avoid $367 Million Medicaid Rebate, Senator Hassan Accuses

<p><a href="https://x.com/pulte/status/1938659666885779503" rel="noopener noreferrer" target="_blank">https://x.com/pulte/status/1938659666885779503</a></p>
<p>&nbsp;</p>
<p><a href="https://x.com/pulte/status/1938659896024551438" title="https://x.com/pulte/status/1938659896024551438">https://x.com/pulte/status/1938659896024551438</a></p>


Politics

FICO

FMCC

FNMA

U.S. Director of Federal Housing FHFA Bill Pulte Posts On X "We are doing a full scale review of all credit bureaus.", On High Interest Rates Says "It's not just people's mortgages. It's car loans, credit cards, etc. These decisions have real impacts on real people."

<p>U.S. President <strong>Donald Trump</strong> said <strong>Bitcoin </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is helping relieve pressure on the U.S. dollar, calling its increasing adoption "<a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46131815/trumps-crypto-advisor-david-sacks-says-july-will-be-a-big-month-says-president-supports-legislation-on-market-structure-and-stablecoins">a great thing for our country</a>."</p>
<p>Speaking about the evolving role of Bitcoin in the economy, Trump said that more people are using it for payments and that the digital asset has become an important part of the financial system.</p>
<p>"I noticed more and more you're paying Bitcoin," Trump said. "People are saying it takes a lot of pressure off the dollar. And it's a great thing for our country."</p>
<p>Trump clarified that he does not personally invest in Bitcoin, but said, "I have my kids and they invest in different things. They do believe in it." </p>
<p>His comment aligns with the known fact that members of the Trump family have been publicly supportive of cryptocurrencies.</p>
<p>In particular, his son <strong>Eric Trump</strong> has emerged as a prominent advocate for Bitcoin. </p>
<p>Eric has regularly spoken at crypto conferences and is involved in American Bitcoin, a company closely aligned with the Trump family that focuses on Bitcoin infrastructure and mining. </p>
<p>Additionally, <strong>Trump Media &amp; Technology Group</strong>, linked to the former president, announced earlier this year that it planned to allocate billions of dollars toward Bitcoin as part of its treasury strategy.</p>
<p><strong>Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46146124/bitcoin-yields-of-up-to-8-are-no-longer-a-fantasy-heres-whos-offering-them">Bitcoin Yields Of Up To 8% Are No Longer A Fantasy: Here&#8217;s Who&#8217;s Offering Them</a></strong></p>
<p>Trump emphasized that his role as president contributed to building an industry that has become strategically significant for the country. "What I did do there is build an industry that's very important," he said.</p>
<p>He also pointed out the geopolitical importance of the U.S. embracing crypto. "You know, we didn't have a [crypto] industry, China would," Trump said.</p>
<p>The Trump family has heavily invested in cryptocurrencies. </p>
<p>Trump Media and Technology Group, the parent company of <strong>Truth Social</strong>, announced in May 2025 a $2.5 billion raise to create a &#8220;Bitcoin treasury.&#8221; </p>
<p>The company, where Trump holds a 53% stake, aims to diversify its $700 million cash reserves into crypto assets, including exchange-traded funds like the proposed "Truth.fi Bitcoin Plus ETF." </p>
<p>Additionally, American Bitcoin, a mining firm co-founded by Eric Trump and backed by<strong> Donald Trump Jr.</strong>, merged with Gryphon Digital Mining to go public on Nasdaq in 2025. </p>
<p>The family also holds a 60% stake in <strong>World Liberty Financial</strong>, which launched a stablecoin, USD1, and raised $550 million in token sales, including a $2 billion investment from an Abu Dhabi-based firm.</p>
<p>Trump's pro-crypto policies include an executive order signed in March 2025 to establish a Strategic Bitcoin Reserve and a Digital Assets Stockpile, aiming to position the U.S. as the "crypto capital of the world." </p>
<p>His administration has paused a dozen federal crypto probes and dropped lawsuits against crypto firms, reversing Biden-era regulations. </p>
<p>However, these moves have sparked concerns about conflicts of interest, with critics like Sen. <strong>Elizabeth Warren</strong> (D-Mass.) accusing Trump of "crypto corruption" due to his family's financial stakes.</p>
<p><strong>Read Next: </strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46140769/north-korean-hackers-top-crypto-exploits-list-but-another-state-may-surprise-you">North Korean Hackers Top Crypto Exploits List, But Another State May Surprise You</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Donald Trump Says 'Bitcoin Takes A Lot Of Pressure Off The Dollar'

WIIM

KTOS

Kratos Defense & Security shares are trading higher after Truist Securities raised its price target on the stock from $38 to $52.

<p>Lottery.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRY#NASDAQ">LTRY</a>, LTRYW))) ("Lottery.com" or "the Company"), a leading technology company transforming the intersection of gaming, sports and entertainment, today confirmed that it is nearing legal proof of a coordinated and unlawful ‘short and distort' campaign targeting the Company. In collaboration with its legal counsel, Paul Hastings LLP, the Company is actively pursuing all individuals and entities engaged in market manipulation intended to damage the Company's share price and reputation.</p>
<p><strong>Christopher Gooding, Independent Director of Lottery.com and a member of the Audit Committee with responsibility for legal affairs, issued the following statement:</strong></p>
<p><i>"There is no doubt that there is an orchestrated campaign against Lottery. The trading metrics and forensic data we have access to clearly indicate both classic ‘short and distort' tactics, and more seriously, a significant volume of naked short selling — illegal trades not backed by actual share ownership.</i></p>
<p><i>"These actors fall into three categories:</i></p>
<ul>
<li><i>"Aggressive and embittered insiders, who appear to be leveraging confidential or insider information from their historical relationships with Lottery.com for self-serving purposes. I outlined elements of these insiders to the judge in a Delaware action earlier this year;</i></li>
<li><i>"Professional short-sellers, aided and abetted by complicit brokers — some of whom are actively engineering mechanisms to facilitate, or are willfully ignoring, illegal naked short activity; and</i></li>
<li><i>"Opportunistic traders, influenced by blogs, shorting platforms, and "pay-to-publish" media articles that amplify false and defamatory narratives. These clearly represent the ‘distort' component of the campaign. Numerous cease-and-desist letters have already been issued.</i><br /><br /><br /><br /><i>"Our message to these parties is unequivocal: We know who you are. We are rapidly securing irrefutable legal evidence of your involvement — including the brokers operating both in the U.S. and offshore in jurisdictions such as the Caribbean. We will pursue damages vigorously and refer the evidence to the appropriate regulatory authorities.</i><br /><br /><br /><br /><i>"Your days are numbered. We will shut you down, and the financial penalties imposed will far exceed the unlawful profits you have sought to extract from our shareholders."</i><br /><br />&nbsp;</li>
</ul>
<p>Lottery.com reiterates its commitment to protecting shareholder value, market integrity, and the long-term growth of its global operations.</p>


Short Sellers

LTRY

Lottery.com Alleges Coordinated Illegal 'Short and Distort' Campaign, Vows Legal Action Against Market Manipulators, Says ""There Is No Doubt That There Is An Orchestrated Campaign Against Lottery. The Trading Metrics And Forensic Data We Have Access To Clearly Indicate Both Classic 'Short And Distort' Tactics, And More Seriously, A Significant Volume Of Naked Short Selling.."

<p>Analysts' ratings for Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) over the last quarter vary from bullish to bearish, as provided by 27 analysts.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">7</td>
<td align="right">14</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $336.0, a high estimate of $376.00, and a low estimate of $265.00. Surpassing the previous average price target of $329.63, the current average has increased by 1.93%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751047308_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The standing of Autodesk among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nay Soe Naing</td>
<td>Berenberg</td>
<td>Raises</td>
<td>Buy</td>
<td>$365.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$376.00</td>
<td>$374.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$361.00</td>
<td>$357.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$345.00</td>
<td>$313.00</td>
</tr>
<tr>
<td>Ken Wong</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$350.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$360.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>Michael Funk</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$330.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$300.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$333.00</td>
<td>$324.00</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$350.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$355.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$370.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Jason Celino</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$323.00</td>
</tr>
<tr>
<td>William Jellison</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$305.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$345.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$374.00</td>
<td>$346.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$340.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$335.00</td>
<td>$303.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$345.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$330.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Jason Celino</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$323.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$350.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>William Jellison</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$265.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$325.00</td>
<td>$365.00</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$310.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Ken Wong</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$350.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Autodesk. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Autodesk compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Autodesk's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Autodesk's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ADSK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Autodesk analyst ratings.</strong></a></p>
<h2>About Autodesk</h2>
<p>Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction; product design and manufacturing; and media and entertainment. Autodesk software enables design, modeling, and rendering needs of these industries. The company has over 4 million paid subscribers across 180 countries.</p>
<h3>Breaking Down Autodesk's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Autodesk's remarkable performance in 3M is evident. As of 30 April, 2025, the company achieved an impressive revenue growth rate of <strong>15.24%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>9.31%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Autodesk's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>5.8%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Autodesk's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>1.42%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Autodesk's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.97</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

ADSK

27 Analysts Assess Autodesk: What You Need To Know

<p>Advanced Energy Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEIS#NASDAQ">AEIS</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $131.83, along with a high estimate of $140.00 and a low estimate of $124.00. Witnessing a positive shift, the current average has risen by 0.38% from the previous average price target of $131.33.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751047296_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Advanced Energy Indus. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$130.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Brian Chin</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$130.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Robert Mason</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$132.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$135.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Robert Mason</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$124.00</td>
<td>$136.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Advanced Energy Indus. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Advanced Energy Indus compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Advanced Energy Indus's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Advanced Energy Indus's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AEIS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Advanced Energy Indus analyst ratings.</strong></a></p>
<h2>All You Need to Know About Advanced Energy Indus</h2>
<p>Advanced Energy Industries Inc provides precision power-conversion measurement and control solutions that transform power into various forms for use in manufacturing and industrial equipment and applications. The firm serves original equipment manufacturers and end customers in the semiconductor, flat panel display, solar panel, and other industrial capital equipment markets. Products include thin-film power-conversion systems, which control and modify raw electrical power into a customizable, predictable power source, and power control modules, which control and measure temperature during manufacturing cycles. A majority of the firm's revenue is generated in United States, with the rest from Mexico, Taiwan, China and All others.</p>
<h3>Advanced Energy Indus's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, Advanced Energy Indus showcased positive performance, achieving a revenue growth rate of <strong>23.54%</strong> as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> Advanced Energy Indus's net margin excels beyond industry benchmarks, reaching <strong>6.1%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>2.03%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Advanced Energy Indus's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.08%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Advanced Energy Indus's debt-to-equity ratio surpasses industry norms, standing at <strong>0.55</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AEIS

Forecasting The Future: 6 Analyst Projections For Advanced Energy Indus

Amer Sports shares are trading higher on possible continued strength after Piper Sandler initiated coverage on the stock yesterday with an Overweight rating and announced a price target of $45.

<p>Ratings for NovoCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated NovoCure and provided 12-month price targets. The average target is $30.75, accompanied by a high estimate of $34.00 and a low estimate of $27.00. Experiencing a 8.21% decline, the current average is now lower than the previous average price target of $33.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751047276_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of NovoCure among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$34.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to NovoCure. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of NovoCure compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for NovoCure's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of NovoCure's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NVCR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on NovoCure analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Get to Know NovoCure Better</h2>
<p>NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.</p>
<h3>Breaking Down NovoCure's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> NovoCure displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>11.91%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> NovoCure's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-22.14%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> NovoCure's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-9.5%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> NovoCure's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-2.76%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.92</strong>, NovoCure faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NVCR

Demystifying NovoCure: Insights From 4 Analyst Reviews

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Netflix</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NFLX, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 155 uncommon options trades for Netflix.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 32% bullish and 36%, bearish.</p>
<p>Out of all of the special options we uncovered, 35 are puts, for a total amount of $2,917,617, and 120 are calls, for a total amount of $16,220,624.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $10.0 to $2310.0 for Netflix over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Netflix's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Netflix's substantial trades, within a strike price spectrum from $10.0 to $2310.0 over the preceding 30 days.</p>
<h3>Netflix Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751047267_0_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NFLX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$935.95</td>
<td>$927.9</td>
<td>$932.12</td>
<td>$400.00</td>
<td>$3.4M</td>
<td align="right">186</td>
<td align="right">24</td>
</tr>
<tr>
<td>NFLX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/17/27</td>
<td>$1319.0</td>
<td>$1309.0</td>
<td>$1309.0</td>
<td>$10.00</td>
<td>$1.0M</td>
<td align="right">11</td>
<td align="right">8</td>
</tr>
<tr>
<td>NFLX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$932.75</td>
<td>$931.35</td>
<td>$931.36</td>
<td>$400.00</td>
<td>$745.3K</td>
<td align="right">186</td>
<td align="right">23</td>
</tr>
<tr>
<td>NFLX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$935.6</td>
<td>$928.9</td>
<td>$930.95</td>
<td>$400.00</td>
<td>$744.7K</td>
<td align="right">186</td>
<td align="right">8</td>
</tr>
<tr>
<td>NFLX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/17/27</td>
<td>$251.5</td>
<td>$246.7</td>
<td>$248.54</td>
<td>$1320.00</td>
<td>$298.2K</td>
<td align="right">32</td>
<td align="right">19</td>
</tr>
</tbody>
</table>
</p>
<h3>About Netflix</h3>
<p>Netflix's relatively simple business model involves only one business, its streaming service. It has the biggest television entertainment subscriber base in both the United States and the collective international market, with more than 300 million subscribers globally. Netflix has exposure to nearly the entire global population outside of China. The firm has traditionally avoided a regular slate of live programming or sports content, instead focusing on on-demand access to episodic television, movies, and documentaries. The firm introduced ad-supported subscription plans in 2022, giving the firm exposure to the advertising market in addition to the subscription fees that have historically accounted for nearly all its revenue.</p>
<p>In light of the recent options history for Netflix, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Netflix</h3>
<ul>
<li>Trading volume stands at 1,784,414, with NFLX's price up by 0.93%, positioned at $1318.88.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 20 days.</li>
</ul>
<h3>What Analysts Are Saying About Netflix</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $1445.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Netflix, which currently sits at a price target of $1425.<br />
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Netflix, which currently sits at a price target of $1450.<br />
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Neutral rating on Netflix with a target price of $1250.<br />
&#x2A; An analyst from Pivotal Research has decided to maintain their Buy rating on Netflix, which currently sits at a price target of $1600.<br />
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Netflix, maintaining a target price of $1500. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Netflix with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

NFLX

Netflix Options Trading: A Deep Dive into Market Sentiment

<p>Providing a diverse range of perspectives from bullish to bearish, 16 analysts have published ratings on Invesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>) in the last three months.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">15</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">12</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $15.17, along with a high estimate of $18.00 and a low estimate of $13.00. A 12.16% drop is evident in the current average compared to the previous average price target of $17.27. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751047267_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A clear picture of Invesco's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$16.75</td>
<td>$16.25</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$16.25</td>
<td>$16.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$15.25</td>
<td>$15.00</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$13.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$13.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$13.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$14.50</td>
<td>$19.50</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$18.50</td>
</tr>
<tr>
<td>Michael Carrier</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Invesco. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Invesco compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Invesco's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Invesco's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/IVZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Invesco analyst ratings.</strong></a></p>
<h2>Get to Know Invesco Better</h2>
<p>Invesco provides investment-management services to retail (67% of managed assets) and institutional (33%) clients. At the end of April 2025, the firm had $1.840 trillion in assets under management spread among its equity (57% of AUM), balanced (3%), fixed-income (22%), alternative investment (7%), and money market (11%) operations. Passive products account for 43% of Invesco's total AUM, including 65% of the company's equity operations and 15% of its fixed-income platform. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 30% of its AUM sourced from Europe, Africa, and the Middle East (15%) and Asia (15%).</p>
<h3>Invesco's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Invesco's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>3.65%</strong> as of 31 March, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>11.19%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.61%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Invesco's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.62%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Invesco's debt-to-equity ratio is below the industry average. With a ratio of <b>0.09</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


16 Analysts Have This To Say About Invesco

<p>Financial giants have made a conspicuous bearish move on Enphase Energy. Our analysis of options history for Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) revealed 23 unusual trades.</p>
<p>Delving into the details, we found 34% of traders were bullish, while 43% showed bearish tendencies. Out of all the trades we spotted, 15 were puts, with a value of $1,267,343, and 8 were calls, valued at $392,990.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $20.0 to $55.0 for Enphase Energy over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Enphase Energy's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Enphase Energy's whale trades within a strike price range from $20.0 to $55.0 in the last 30 days. </p>
<h3>Enphase Energy Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751047262_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ENPH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$22.2</td>
<td>$18.65</td>
<td>$21.2</td>
<td>$55.00</td>
<td>$424.0K</td>
<td>1.1K</td>
<td>200</td>
</tr>
<tr>
<td>ENPH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$2.55</td>
<td>$2.48</td>
<td>$2.55</td>
<td>$40.00</td>
<td>$386.5K</td>
<td>25.0K</td>
<td>1.6K</td>
</tr>
<tr>
<td>ENPH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$5.1</td>
<td>$5.0</td>
<td>$5.05</td>
<td>$45.00</td>
<td>$128.7K</td>
<td>755</td>
<td>284</td>
</tr>
<tr>
<td>ENPH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/11/25</td>
<td>$3.4</td>
<td>$3.35</td>
<td>$3.39</td>
<td>$41.00</td>
<td>$67.9K</td>
<td>101</td>
<td>401</td>
</tr>
<tr>
<td>ENPH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$6.85</td>
<td>$6.75</td>
<td>$6.75</td>
<td>$45.00</td>
<td>$55.3K</td>
<td>8.6K</td>
<td>84</td>
</tr>
</tbody>
</table>
</p>
<h3>About Enphase Energy</h3>
<p>Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.</p>
<p>After a thorough review of the options trading surrounding Enphase Energy, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Current Position of Enphase Energy</h3>
<ul>
<li>With a volume of 5,169,315, the price of ENPH is down -8.0% at $39.56. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 25 days.</li>
</ul>
<h3>What The Experts Say On Enphase Energy</h3>
<p>4 market experts have recently issued ratings for this stock, with a consensus target price of $42.25.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Keybanc downgraded its action to Underweight with a price target of $31.<br />
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Enphase Energy, maintaining a target price of $42.<br />
&#x2A; Consistent in their evaluation, an analyst from Mizuho keeps a Outperform rating on Enphase Energy with a target price of $53.<br />
&#x2A; An analyst from Citigroup persists with their Sell rating on Enphase Energy, maintaining a target price of $43. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Enphase Energy with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


ENPH

Enphase Energy Options Trading: A Deep Dive into Market Sentiment

<p>Throughout the last three months, 6 analysts have evaluated Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $83.33, along with a high estimate of $110.00 and a low estimate of $60.00. Experiencing a 5.31% decline, the current average is now lower than the previous average price target of $88.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751047257_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The perception of Qorvo by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Gary Mobley</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$75.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Announces</td>
<td>Buy</td>
<td>$95.00</td>
<td>-</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$60.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Qorvo. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Qorvo compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Qorvo's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Qorvo's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/QRVO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Qorvo analyst ratings.</strong></a></p>
<h2>Delving into Qorvo's Background</h2>
<p>Qorvo represents the combined entity of RF Micro Devices and TriQuint Semiconductor, which merged in January 2015. The company specializes in radio frequency filters, power amplifiers, and front-end modules used in many of the world's most advanced smartphones. Qorvo also has a suite of products sold into a variety of nonsmartphone end markets, such as wireless base stations, cable TV and networking equipment, and infrastructure and military applications.</p>
<h3>Qorvo's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3M period, Qorvo faced challenges, resulting in a decline of approximately <strong>-7.6%</strong> in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Qorvo's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>3.61%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>0.93%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Qorvo's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.53%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.46</strong>, caution is advised due to increased financial risk.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


QRVO

Demystifying Qorvo: Insights From 6 Analyst Reviews

<p>Deep-pocketed investors have adopted a bearish approach towards Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SNOW usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 58 extraordinary options activities for Snowflake. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 36% leaning bullish and 46% bearish. Among these notable options, 25 are puts, totaling $1,083,969, and 33 are calls, amounting to $1,908,763.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $130.0 and $300.0 for Snowflake, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for Snowflake options trades today is 1026.41 with a total volume of 8,689.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Snowflake's big money trades within a strike price range of $130.0 to $300.0 over the last 30 days.</p>
<h3>Snowflake Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751047257_0_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/20/26</td>
<td>$65.55</td>
<td>$65.55</td>
<td>$65.55</td>
<td>$170.00</td>
<td>$195.9K</td>
<td>32</td>
<td align="right">30</td>
</tr>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$8.75</td>
<td>$8.7</td>
<td>$8.7</td>
<td>$250.00</td>
<td>$143.5K</td>
<td>5.2K</td>
<td align="right">289</td>
</tr>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$6.25</td>
<td>$5.65</td>
<td>$5.75</td>
<td>$290.00</td>
<td>$132.2K</td>
<td>684</td>
<td align="right">231</td>
</tr>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/03/25</td>
<td>$2.85</td>
<td>$2.69</td>
<td>$2.8</td>
<td>$225.00</td>
<td>$111.7K</td>
<td>2.7K</td>
<td align="right">710</td>
</tr>
<tr>
<td>SNOW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$12.45</td>
<td>$12.4</td>
<td>$12.45</td>
<td>$190.00</td>
<td>$88.3K</td>
<td>1.1K</td>
<td align="right">72</td>
</tr>
</tbody>
</table>
</p>
<h3>About Snowflake</h3>
<p>Founded in 2012, Snowflake is a fully managed platform that consolidates data hosted on different public clouds for centralized analytics and governance. Snowflake's cloud-native architecture allows users to independently scale the compute and storage layers, providing customers with optimized performance at lower costs. The company's data lake and data warehouse products support a variety of use cases, including business analytics, data engineering, and artificial intelligence. Snowflake is widely used by Fortune 2000 companies in financial services, media, and retail sectors.</p>
<p>Following our analysis of the options activities associated with Snowflake, we pivot to a closer look at the company's own performance.</p>
<h3>Snowflake's Current Market Status</h3>
<ul>
<li>Trading volume stands at 2,205,891, with SNOW's price up by 0.14%, positioned at $222.22.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 54 days.</li>
</ul>
<h3>Professional Analyst Ratings for Snowflake</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $241.4.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Macquarie continues to hold a Neutral rating for Snowflake, targeting a price of $210.<br />
&#x2A; Reflecting concerns, an analyst from JMP Securities lowers its rating to Market Outperform with a new price target of $245.<br />
&#x2A; An analyst from Evercore ISI Group persists with their Outperform rating on Snowflake, maintaining a target price of $240.<br />
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for Snowflake, targeting a price of $250.<br />
&#x2A; Reflecting concerns, an analyst from Morgan Stanley lowers its rating to Overweight with a new price target of $262.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Snowflake, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


SNOW

Snowflake Unusual Options Activity

<p><strong>Abbott Laboratories's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) short percent of float has risen 3.45% since its last report. The company recently reported that it has <strong>20.80 million shares sold short</strong>, which is 1.2% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 4.4 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Abbott Laboratories Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751047242_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Abbott Laboratories has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Abbott Laboratories's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Abbott Laboratories's peer group average for short interest as a percentage of float is 5.31%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Ideas

How Is The Market Feeling About Abbott Laboratories?

<p>BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $1053.07, with a high estimate of $1178.00 and a low estimate of $950.00. This current average has decreased by 4.0% from the previous average price target of $1097.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751047238_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of BlackRock among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$1115.00</td>
<td>$994.00</td>
</tr>
<tr>
<td>Stephen Biggar</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$1090.00</td>
<td>$1028.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1105.00</td>
<td>$1035.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$980.00</td>
<td>$1010.00</td>
</tr>
<tr>
<td>William Katz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1100.00</td>
<td>$1200.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$988.00</td>
<td>$1046.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$990.00</td>
<td>$950.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1035.00</td>
<td>$1065.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1010.00</td>
<td>$1045.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1032.00</td>
<td>$1251.00</td>
</tr>
<tr>
<td>Mike Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1124.00</td>
<td>$1275.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$950.00</td>
<td>$1210.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1178.00</td>
<td>$1196.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1046.00</td>
<td>$1053.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to BlackRock. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of BlackRock compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for BlackRock's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Capture valuable insights into BlackRock's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BLK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on BlackRock analyst ratings.</strong></a></p>
<h2>Delving into BlackRock's Background</h2>
<p>BlackRock is the largest asset manager in the world, with $11.584 trillion in assets under management at the end of March 2025. Its product mix is diverse, with 53% of managed assets in equity strategies, 26% in fixed income, 9% in multi-asset classes, 8% in money market funds, and 4% in alternatives. Passive strategies account for two thirds of long-term AUM, with the company's ETF platform maintaining a leading market share domestically and on a global basis. Product distribution is weighted more toward institutional clients, which by our calculations account for around 80% of AUM. BlackRock is geographically diverse, with clients in more than 100 countries and more than one third of managed assets coming from investors domiciled outside the US and Canada.</p>
<h3>Breaking Down BlackRock's Financial Performance</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> BlackRock's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>11.59%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> BlackRock's net margin excels beyond industry benchmarks, reaching <strong>28.62%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> BlackRock's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>3.16%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> BlackRock's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.08%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> BlackRock's debt-to-equity ratio is below the industry average at <strong>0.3</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Verdict: BlackRock In The Eyes Of 14 Experts

<p><strong>Sempra's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>) short percent of float has risen 6.93% since its last report. The company recently reported that it has <strong>7.06 million shares sold short</strong>, which is 1.08% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.02 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Sempra Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751047237_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Sempra has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Sempra's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Sempra's peer group average for short interest as a percentage of float is 3.48%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


What Does the Market Think About Sempra?

Health Care

Press Releases

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Management

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

Earnings

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update

Rapport Therapeutics to Host 2025 Investor and Analyst Day

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference

Comments

Rapport Therapeutics

Noticias

Últimas noticias sobre Rapport Therapeutics (NASDAQ:RAPP) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL